Project Grant R43GM134729

This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $440,287 to GE Medical Systems Information Technologies, Inc. to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This approach aims to democratize biobanking for low-resource institutes by enabling molecular analysis from smaller tumor samples, including those less than 10,000...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

This $295,924 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to develop and demonstrate a high-yield microfluidic device for the enrichment and capture of CD3+ T cells. This device is intended to improve the manufacturing of autologous and allogenic engineered cell therapies such as CAR-T, which currently have time-consuming and costly production processes. The key objectives are to (1)...

This National Science Foundation (NSF) Engineering grant award, under the CFD Program 47.041, provides $150,000 to the University of Georgia Research Foundation to develop novel methods for high-throughput, antibody-free cell sorting. The project, titled "EAGER: IMPRESS-U: HIGH-THROUGHPUT AGILE INTERFACES FOR CELL SORTING," aims to create an alternative, scalable approach to efficiently separate therapeutic cells from unwanted or damaged cells for biomedical applications. The...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...

This Project Grant award of $231,413 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a novel SPINEX (Separation-Processing Integration for Extracellular Vesicles) technology to streamline sample preparation for extracellular vesicle (EV) analysis. The project, awarded to The General Hospital Corporation (doing business as Massachusetts General Hospital), has two key objectives: Implement a fully automated, multi-functional SPINEX...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $814,209 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to develop CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy. The key objectives are to: 1) optimize nanoparticle formulations loaded with gene-editing agents and functionalize them for targeting, 2) evaluate the...

This National Science Foundation (NSF) Project Grant award under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000 to Cellecho, Inc. to develop a microchip-based technology that leverages sound waves and electric fields to manipulate cells and sequentially deliver customizable combinations of genetic materials. The goal is to make advanced cell engineering more accessible and streamlined, accelerating discoveries in cell and gene therapy, biotechnology,...

The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...